NLOSSNLOSS 1. Whittington Hospital & 2. UCL Serum Insulin & Blood Pressure in Obesity may be Linked to Subcutaneous & Omental Fat ADMA Content P A Sufi.

Slides:



Advertisements
Similar presentations
ADIPONECTIN Its emerging role in Atherosclerosis, Metabolic Syndrome and Insulin Resistance RT ERASMUS Chemical Pathology, Tygerberg Hospital, NHLS &University.
Advertisements

DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
Regulation of food intake. Food intake Regulation –Endocrine Adipose tissue Pancreas Liver Muscle –CNS.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
Blood glucose levels and Vascular Disease. Chronic elevation of blood glucose levels leads to the endothelium cells taking in more glucose than normal.
Retinol Binding Protein-4 levels in thyroid overt and subclinical dysfunction Kokkinos Spiridon, Tiaka Elisavet, Manolakis Anastasios, Papanas Nikolaos,
By Hussam A.S. Murad Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad Department of Pharmacology.
MCB 135K: Discussion.
S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
Effects of Low-Fat Dairy Consumption on Markers of Low- Grade Systemic Inflammation and Endothelial Function in Overweight and Obese Subjects: An Intervention.
Risk factors of Heart disease Dr. Mahmoudian.. Risk factors for coronary artery atherosclerosis Hyperlipidemia and dyslipidemia Hypertension Cigarette.
Comparison of PI vs PI  ATV/r vs DRV/rATADAR. ATV/r 300/100 mg + TDF/FTC qd N = 91 N = 89 DRV/r 800/100 mg + TDF/FTC qd  Design Randomisation 1: 1 Open-label.
Goals: 1) Understand the mechanism for ↑LDL in Type II diabetes 2) Having previously established the link between endothelial cell damage (loss of inhibitory.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
Endocrine Block | 1 Lecture | Dr. Usman Ghani
Adiponectinemia, glucose status, insulin secretion and insulin resistance in obese women: influence of weight loss 1) To compare variation in adiponectin.
METABOLIC Syndrome: a Global Perspective
SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.
Physical Wellness Health A / B. Disease Prevention Regular physical activity lowers your risk of many chronic and disabling disease. Why? What is a chronic.
Diabetes Mellitus (Lecture 2). Type 2 DM 90% of diabetics (in USA) Develops gradually may be without obvious symptoms may be detected by routine screening.
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
Factors Released from Adipose Tissue and their Physiological Relevance
Assessment of Radial Pulse Wave Analysis, Insulin Resistance, and Glucose Homeostasis in African Americans at High Risk for Developing Type 2 Diabetes.
Obesity Dr. Sumbul Fatma. Obesity A disorder of body weight regulatory systems Causes accumulation of excess body fat >20% of normal body weight Obesity.
Mechanisms linking obesity with cardiovascular disease
Focus On OBESITY, METABOLISM, AND DISEASE RISK. Obesity and Disease Risk Copyright 2012, John Wiley & Sons Canada, Ltd.
Note Midterm - 4 March in class. Note Signal peptide-A sequence of amino acids that determine whether a protein will be formed on the rough endoplasmic.
Coagulation / Fibrinolytic Factors in PCOS. The Alternative Hypothesis : Conversely, PCOS women may be protected from later life onset of CHD by the altered.
大豆蛋白質對慢性腎衰竭患者血壓、血脂與腎功能的影響 Hyperlipidemic factors contribute to the high cardiovascular risk in hemodialysis patients and may accelerate the progression.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年6月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Atherosclerosis process... By Enzyme needed and product in thrombosis By 3 CVD conditions By 3 hormones involved in glucose regulation By Sphygomamo- meter.
Contemporary Management of Cardiometabolic Risk. A continuing epidemic: 2 of 3 US adults are overweight or obese National Health and Nutrition Examination.
Note Midterm - 7 March in class. Note Signal peptide-A sequence of amino acids that determine whether a protein will be formed on the rough endoplasmic.
Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.
Cardiovascular Disease (CVD) A general term for diseases of the heart and/or blood __________ _____% of all deaths annually 2,600 American deaths each.
Double Jeopardy. International Diabetes Federation Diabetes State of raised blood glucose (hyperglycaemia) associated with premature mortality Pancreas.
Obesity Dr. Sumbul Fatma. Obesity A disorder of body weight regulatory systems Causes accumulation of excess body fat >20% of normal body weight Obesity.
Cardiovascular & Metabolic Complications of Cushing’s Syndrome Presented by: Saeed Behradmanesh, MD Internist, Endocrinologist.
Metabolic Syndrome Darwin Deen, MD, MS Albert Einstein College of Medicine Gina Lopez, MSII Sophie Davis School of Biomedical Education.
Comparison of Asymmetric DimethylArginine Levels and Coronary Artery Calcifications in Different Stages of Chronic Kidney Disease and Kidney Transplantation.
Comparison of some cardiometabolic risk factors in peri-urban adolescent school learners in mthatha, South Africa. Presented by BN Nkeh-Chungag.
Insulin Resistance Progression to Diabetes Part 3.
LAB (6): LIPIDS PROFILE KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2013.
Source: International Chair on Cardiometabolic Risk Metabolic Syndrome and Adipose Tissue Yuji Matsuzawa, MD, PhD Director.
TEMPLATE DESIGN © CONTINUOUS GLUCOSE MONITORING, ORAL GLUCOSE TOLERANCE, AND INSULIN – GLUCOSE PARAMETERS IN ADOLESCENTS.
Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.
DOES LEPTIN LEVELS AFFECT CARDIOMETABOLIC FACTORS INDEPENDENTLY OF ADIPOSITY IN OBESE BRAZILIAN CHILDREN? Maria Edna Melo 1,2,3, Clarissa TH Fujiwara 1,
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Lipoprotein Structure, Function, and Metabolism
Is atherosclerosis a metabolic disease?
Endocrine Block 1 Lecture Dr. Usman Ghani
Endocrine Block Dr. Usman Ghani
Chapter 7 Metabolic syndrome
Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS
Endocrine Block | Dr. Usman Ghani
Elevated Circulating Levels of Inflammatory Markers in
Department of Internal Medicine
Coagulation/Fibrinolytic Factors in PCOS
By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology
Obesity Dr. Sumbul Fatma.
Blood glucose levels and obesity
Endocrine Block 1 Lecture Dr. Usman Ghani
Effect of Metabolic Surgery on diabetes and hypertension
The pathology of cardiovascular disease (CVD)
Vascular biology of metabolic syndrome
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
Type 2 diabetes: Overlap of clinical conditions
What do I remember? What is the effect of chronically elevated blood glucose levels on blood vessels? What cardiovascular diseases are a consequence of.
Comparison of PI vs PI ATV vs ATV/r BMS 089
Section overview: Cardiometabolic risk reduction
Presentation transcript:

NLOSSNLOSS 1. Whittington Hospital & 2. UCL Serum Insulin & Blood Pressure in Obesity may be Linked to Subcutaneous & Omental Fat ADMA Content P A Sufi 1, D Heath 1, K Mcdougall 1, L Jones 1, V Mohamedi 2

NLOSSNLOSS Whittington Hospital & UCL Context Obesity is an excess of adipose tissue (fat). It is the most prevalent nutritional disorder associated with significantly increased risk for CVD morbidity and mortality. The exact role and mechanisms by which obesity promotes cardiovascular risk is poorly understood. Obesity is associated with adverse changes in circulating CVD risk factors, which may be involved in the development of T2DM and CVD.

NLOSSNLOSS Whittington Hospital & UCL Metabolic Syndrome & NO Endothelial function determined by bioavailability of NO, and insulin sensitivity modulated by adiposity and altered NO levels, may explain both the endothelial dysfunction and insulin resistance of obesity. Although it has been postulated that adipose tissue-derived mediators (leptin, TNF-a, IL-6 and adiponectin) act on the endothelium to produce detrimental effects, to date none has been clearly identified. Asymmetric dimethylarginine (ADMA) – a metabolic by-product of protein modification in the cytoplasm - is an endogenous inhibitor of all forms of nitric oxide synthase (NOS) and is found in plasma. Nitric Oxide Dilates blood vessels Reduces monocyte stickinessReduces oxidation of LSL cholesterol Reduces arterial smooth muscle cell multiplication Reduces platelet stickiness Reduces superoxide radical release

NLOSSNLOSS Whittington Hospital & UCL ADMA inhibition of NO: Oxygen Carbon Nitrogen Hydrogen OxygenADMASuperoxide radical ADMA +=+ - L-arginineOxygenL-citrulineNOWater +=+++=++

NLOSSNLOSS Whittington Hospital & UCL Effects of ADMA Plasma ADMA is raised in CVD, hypertension, atherosclerosis and T2DM. ADMA levels are also elevated in morbidly obese subjects. Circulating ADMA levels correlate closely with degree of insulin resistance and is independently associated with BMI. Significant reduction in systemic ADMA, along with improvement in several components of the metabolic syndrome, follows bariatric surgery and weight loss. Elevated ADMA Level (Inhibition of NOS) Atherosclerosis Hypercholesterolaemia Hypertension OSA CCF Erectile dysfunction CVA Vascular dementia Liver failure Diabetes Pre-eclampsia Chronic renal failure }

NLOSSNLOSS Whittington Hospital & UCL PRMT: protein arginine methyl transferase; DDAH: dimethylarginine dimethylaminohydrolase; ASS: argininosuccinate synthase; ASL: argininosuccinate lyase; AR: arginase; NOS: nitric oxide synthase; OAT: ornithine aminotransferase; ODC: ornithine decarboxylase ADMA is synthesized by PRMTs and hydrolysed by DDAH: all components of this pathway are expressed in adipose tissue. ADMA/DDAH Pathway

NLOSSNLOSS Whittington Hospital & UCL Aims To investigate the depot-specific differences in ADMA content and release, and the expression of DDAH 1 & 2 (the enzymes responsible for ADMA hydrolysis) and PRMTs (the enzymes responsible for the synthesis of ADMA) in human omental and subcutaneous adipose tissue. PRMT: protein arginine methyl transferase; DDAH: dimethylarginine dimethylaminohydrolase;

NLOSSNLOSS Whittington Hospital & UCL Method A cross-sectional cohort study of Caucasian morbidly obese, non-diabetic female patients undergoing gastric banding or cholecystectomy Circulating, adipose tissue content and generation of ADMA and tissue expression of DDAH-1 and -2 mRNA, and PRMT-3 protein were determined from omental and subcutaneous depots. In a subgroup of patients (n=9) the stroma-vascular fraction was separated from whole adipose tissue and ADMA and DDAH were analysed. Insulin resistance was assessed by HOMA-IR and body fat content by electrical bio-impedance. Exclusion: DM, CHD, HTN, conditions or agents affecting cytokine release e.g; aspirin, NSAIDs, steroids, warfarin, ACE inhibitors, statins HOMA-IR: Homeostatic Model Assessment-Insulin Resistance =fasting plasma insulin (µIU/mL) x fasting plasma glucose (mmol/L) / 22.5

NLOSSNLOSS Whittington Hospital & UCL HOMA-IR Anthropometric Measurements ( Body stat analyser ) Tissue ADMA Organ Culture ADMA Stroma-Vascular Fraction (SVF) separated Fat biopsy at surgery Schema of Methods Fasting Blood Lipids Glucose Insulin ADMA BMI % Body Fat % lean Mass HPLC mRNA for DDAH Protein for PRMT HPLC: High performance liquid chromatography

NLOSSNLOSS Whittington Hospital & UCL Anthropometric and Metabolic Characteristics of Patients Number16 Age (years)43.4 (7.9) BMI (kg/m 2 )43.8 (10.1) Body fat (%)52.6 (7.0) Lean mass (%)47.4 (7.0) Insulin (MU/l)7.7 (7.1 – 15.0) Glucose5.18 (0.45) Total Cholesterol (mmol/l)4.56 (0.93) HDL cholesterol (mmol/l)1.21 (0.24) LDL cholesterol (mmol/l)2.8 (0.92) Triglycerides (mmol/l)1.12 (0.32) ADMA (mM)1.95 ( ) Adiponectin (mg/ml)5.6 ( ) Leptin (ng/ml)28.7 ( ) IL-6 (pg/ml)2.22 ( ) MCP-1 (pg/ml)221.3 ( ) RANTES (ng/ml)57.0 ( )

NLOSSNLOSS Whittington Hospital & UCL Results 1 Serum insulin and systolic blood pressure correlated directly with subcutaneous ADMA content. ADMA release was significantly higher from the omental depot (p=0.025) and correlated with BMI. While DDAH2 expression was higher compared to DDAH1 in both the whole adipose tissue and the stroma-vascular fraction of both depots No depot-specific difference in the expression of either isoform was detected. However, PRMT-3 protein expression was higher in the omental compared to the sub-cutaneous adipose tissue.

NLOSSNLOSS Whittington Hospital & UCL ADMA Release n=13, Comparison by Wilcoxon Rank test Omental Subcutaneous ADMA release (  M/gr tisuue/24 p = 0.025

NLOSSNLOSS Whittington Hospital & UCL DDAH Expression – Adipose Tissue n=15, Comparisons by Wilcoxon Rank test

NLOSSNLOSS Whittington Hospital & UCL DDAH Expression – Adipose Tissue vs SVF n= 9, Comparisons by Wilcoxon Rank test

NLOSSNLOSS Whittington Hospital & UCL Results 2 Om ADMA release α BMI (r = 0.56, p = 0.04) HOMA-R αSc tissue ADMA (r = 0.83, p = 0.04) Om tissue ADMA (r = 0.70, p = 0.08) OM: Omental; SC: Subcutaneous; HOMA-IR: Homeostatic Model Assessment-Insulin Resistance

NLOSSNLOSS Whittington Hospital & UCL Conclusion The direct associations of omental ADMA release and BMI and higher omental ADMA content points to a link between visceral obesity and endothelial dysfunction. The depot-specific generation in ADMA may be due to differences in the synthetic enzymes or to changes in the activity, rather than mRNA expression, of DDAH. Modulation of adipose ADMA generation may reduce obesity associated co-morbidities.